Literature DB >> 25911301

Current kinase inhibitors cover a tiny fraction of fragment space.

Hongtao Zhao1, Amedeo Caflisch2.   

Abstract

We analyze the chemical space coverage of kinase inhibitors in the public domain from a fragment point of view. A set of 26,668 kinase inhibitors from the ChEMBL database of bioactive molecules were decomposed automatically by fragmentation at rotatable bonds. Remarkably, about half of the resulting 10,302 fragments originate from inaccessible libraries, as they are not present in commercially available compounds. By mapping to the established kinase pharmacophore models, privileged fragments in sub-pockets are identified, for example, the 5681 ring-containing fragments capable of forming bi-dentate hydrogen bonds with the hinge region in the ATP binding site. Surprisingly, hinge-binding fragments in current kinase inhibitors cover only 1% of the potential hinge-binders obtained by decomposing a library of nearly 7.5 million commercially available compounds, which indicates that a large fraction of chemical space is unexplored.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemical space; Fragment-based drug discovery; Fragmentation; Kinase; Tricyclic ring systems

Mesh:

Substances:

Year:  2015        PMID: 25911301     DOI: 10.1016/j.bmcl.2015.04.005

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  8 in total

1.  Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases.

Authors:  Jing Dong; Hongtao Zhao; Ting Zhou; Dimitrios Spiliotopoulos; Chitra Rajendran; Xiao-Dan Li; Danzhi Huang; Amedeo Caflisch
Journal:  ACS Med Chem Lett       Date:  2014-09-29       Impact factor: 4.345

Review 2.  Rings in Clinical Trials and Drugs: Present and Future.

Authors:  Jonathan Shearer; Jose L Castro; Alastair D G Lawson; Malcolm MacCoss; Richard D Taylor
Journal:  J Med Chem       Date:  2022-06-22       Impact factor: 8.039

3.  Novel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents.

Authors:  Md Maqusood Alam; Su-Chan Lee; Yujin Jung; Hye Jeong Yun; Hye-Young Min; Ho Jin Lee; Phuong Chi Pham; Jayoung Moon; Dah In Kwon; Bumhee Lim; Young-Ger Suh; Jeeyeon Lee; Ho-Young Lee
Journal:  Oncotarget       Date:  2015-12-01

4.  Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR.

Authors:  Dilip Narayanan; Osman A B S M Gani; Franz X E Gruber; Richard A Engh
Journal:  J Cheminform       Date:  2017-07-04       Impact factor: 5.514

5.  Discovery of a novel kinase hinge binder fragment by dynamic undocking.

Authors:  Moira Rachman; Dávid Bajusz; Anasztázia Hetényi; Andrea Scarpino; Balázs Merő; Attila Egyed; László Buday; Xavier Barril; György M Keserű
Journal:  RSC Med Chem       Date:  2020-03-04

6.  Screening a protein kinase inhibitor library against Plasmodium falciparum.

Authors:  Irene Hallyburton; Raffaella Grimaldi; Andrew Woodland; Beatriz Baragaña; Torsten Luksch; Daniel Spinks; Daniel James; Didier Leroy; David Waterson; Alan H Fairlamb; Paul G Wyatt; Ian H Gilbert; Julie A Frearson
Journal:  Malar J       Date:  2017-11-07       Impact factor: 2.979

7.  Screening of a Novel Fragment Library with Functional Complexity against Mycobacterium tuberculosis InhA.

Authors:  Federica Prati; Fabio Zuccotto; Daniel Fletcher; Maire A Convery; Raquel Fernandez-Menendez; Robert Bates; Lourdes Encinas; Jingkun Zeng; Chun-Wa Chung; Paco De Dios Anton; Alfonso Mendoza-Losana; Claire Mackenzie; Simon R Green; Margaret Huggett; David Barros; Paul G Wyatt; Peter C Ray
Journal:  ChemMedChem       Date:  2018-02-19       Impact factor: 3.466

8.  Comparative Assessment of Protein Kinase Inhibitors in Public Databases and in PKIDB.

Authors:  Colin Bournez; Fabrice Carles; Gautier Peyrat; Samia Aci-Sèche; Stéphane Bourg; Christophe Meyer; Pascal Bonnet
Journal:  Molecules       Date:  2020-07-15       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.